Data on the use of GLP1RAs in transplanted patients is scarce
The companys behavioral science team has been gathering data since the September launch of its Noom GLP-1 Rx product to support claims related to the following dimensions: Improved medication persistence , measured as total weeks adhered Improved medication adherence , measured as % of doses skipped Decreased side effect prevalence , measured as incidence rate and severity Improved lean muscle mass preservation , measured through Noom Body Scan Improved weight loss outcomes across a full sample of study participants "Every day, we're focused on helping people everywhere to live better longer, and entering into the PDURS space is an important next step in making that happen," continued Cook
Safety data in humans are restricted to short-term topical or local use with mild adverse reports
Recommended for you: Your friendly guide to GLP-1 weight loss: what works, what doesnt and whats next Why GLP-1 heart benefits go beyond weight loss GLP-1s are often described as weight-loss shots, but cardiologists see them differently
People with a BMI between 30 and 34 may also be candidates if they have weight-related health issues
Skin rash or itching (rare)